This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
New Horizons in Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes with SGLT-2, GLP-1 RAs and DPP-4 Based Therapies

New Horizons in Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes with SGLT-2, GLP-1 RAs and DPP-4 Based Therapies

Format

Webcast

Time to Complete

1 hour

Released

June 14, 2019

Expires

June 14, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour

Accredited Provider

Jointly provided by Amedco and MedNet, LLC.

Commercial Supporters

Supported by AstraZeneca

Program Description

This webcast is intended to improve care of patients by reducing cardiovascular disease risk in patients with type 2 diabetes with SGLT-2, GLP-1 RAs and DPP-4 based therapies by accelerating adoption of new evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of diabetologists, cardiologists, endocrinologists, internal medicine physicians, family medicine physicians, physician assistants, nurse practitioners, registered nurses and allied healthcare professionals involved in the diagnosis and treatment of patients with type 2 diabetes.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Identify and select existing antihyperglycemic treatment for patients with T2D based on newer guidelines, benefits, risks of second-line treatments, patient profiles and preferences
  • Outline the benefits and risks of SGLT-2, GLP1-RAs and DPP-4 inhibitors in reducing cardiovascular disease (CVD) risk in patients with T2D

Conflict Of Interest Disclosure Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Faculty

George Grunberger, MD
Chairman
Grunberger Diabetes Institute
Bloomfield Hills, Michigan
Clinical Professor
Internal Medicine and Molecular Medicine & Genetics
Wayne State University School of Medicine
Detroit, MI
Professor
Internal Medicine, Oakland University William Beaumont School of Medicine
Rochester, MI

Dr. Grunberger discloses that he is a consultant of Lilly, Novo Nordisk, Sanofi, Boehringer Ingelheim; and was on advisory board of AstraZeneca, Novo Nordisk, and received research support from Novo Nordisk, Medtronic.

Darren K. McGuire, MD
Distinguished Teaching Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Dr. McGuire discloses that he is a consultant of Novo Nordisk, Sanofi-Aventis, Boehringer Ingelheim, Lilly USA, Merck & Co, AstraZeneca, Metavant, Applied Therapeutics and was on the clinical trials leadership of Merck & Co, Pfizer, AstraZeneca, Janssen, Lilly USA, Boehringer Ingelheim, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline, Sanofi-Aventis

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

George Grunberger, MD , listed his disclosures under the Faculty heading above.

Darren K. McGuire, MD, listed his disclosures under the Faculty heading above.

Kamatham A. Naidu, PhD (MedNet, LLC), has no relevant financial relationships to disclose.
Brian Waggoner (MedNet, LLC), has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco), has no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Amedco designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Amedco designates this enduring material for a maximum of 1.00 contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

NON-ENDORSEMENT OF PRODUCTS
Amedco does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating and receiving CME credit for this webcast. During the period June 14, 2019 through June 14, 2020, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or above on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at 651-789-3730.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Amedco observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue